▼ Summary
– Herbalife is acquiring assets from the London-based startup Bioniq, which creates personalized supplement regimens using blood biomarker data, in a deal worth up to $150 million.
– The guaranteed purchase price is $55 million paid over five years, with the remaining $95 million contingent on Bioniq meeting future performance milestones.
– Bioniq’s core technology uses blood test results and health questionnaires to generate individualized formulas, moving beyond generic multivitamins.
– The acquisition provides Herbalife with a data-driven personalization platform for its global distributor network, addressing a key industry trend.
– Bioniq had notable prior investments, including from footballer Cristiano Ronaldo, who is also a Herbalife global nutrition partner.
In a strategic move to capture the growing demand for customised wellness, Herbalife has agreed to acquire key assets from the London startup Bioniq. The deal, structured with significant performance incentives, could ultimately be worth up to $150 million. This acquisition provides the global nutrition giant with a sophisticated, data-driven platform for creating personalised supplement regimens, directly addressing a major industry shift.
The financial terms reveal a carefully structured agreement. Herbalife will pay a guaranteed $55 million over five years, beginning with a $10 million payment at closing. The remaining $95 million is entirely contingent on Bioniq achieving specific future performance milestones, making the full $150 million a maximum potential value. The transaction is anticipated to finalise in the second quarter of 2026, pending standard regulatory approvals.
Founded in 2019 by former professional basketball player Vadim Fedotov, Bioniq has built its business on the premise that generic multivitamins are inefficient. Instead, the company uses blood biomarker data from individual clients to formulate unique daily supplement blends. Its algorithm processes this biomarker information alongside detailed health questionnaires, supported by a database of over six million biomarker data points collected worldwide. Following the acquisition’s close, Fedotov and other key Bioniq staff will join Herbalife’s leadership team.
For Herbalife, which operates a vast network of independent distributors across 95 markets, this deal fills a critical gap. The company’s traditional model, while effective at scale, has lacked the infrastructure for a truly individualised product experience. Bioniq’s proprietary technology delivers the personalised nutrition infrastructure Herbalife has sought, allowing it to compete more directly with modern healthtech brands. The agreement also includes an option for Herbalife to acquire Bioniq LAB, a separate platform focused on small molecules and peptides, hinting at a potential future expansion into more advanced bioactive compounds.
Bioniq’s recent financial history underscores its momentum. The startup closed a $15 million Series B round in July 2024, led by HV Capital and Unbound, achieving a $75 million valuation. That figure climbed to $82 million later that year following a significant investment from football icon Cristiano Ronaldo, who had been a customer since 2022. The connection deepens with this acquisition, as Ronaldo also serves as a Herbalife global nutrition partner. Fellow footballer Diogo Dalot also invested over one million euros in Bioniq in early 2025.
The integration plan is already taking shape. Bioniq’s personalised supplement offerings are expected to become available through Herbalife’s independent distributor network in select European and U. S. markets before the end of this year, marking a new chapter for both companies in the competitive wellness landscape.
(Source: The Next Web)
